**Trial Design**

**331** Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Renato D. Lopes, MD, PhD, John H. Alexander, MD, MHS, Sana A. Al-Khatib, MD, MHS, Jack Ansell, MD, Raphael Diaz, MD, J. Donald Easton, MD, Bernard J. Gersh, MD, ChB, DPhil, Christopher B. Granger, MD, Michael Hanna, MD, John Horowitz, MD, Elaine M. Hylek, MD, MPH, John J.V. McMurray, MD, Freek W.A. Verheugt, MD, PhD, and Lars Wallentin, MD, PhD on behalf of the ARISTOTLE Investigators, Durham, NC; New York, NY; Santa Fe, Argentina; Providence, RI; Rochester, MN; Princeton, NJ; Adelaide, Australia; Boston, MA; Glasgow, United Kingdom; Nijmegen, The Netherlands; and Uppsala, Sweden

**340** Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
The Executive Steering Committee on behalf of the ROCKET AF Study Investigators, Durham, NC

**348** Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
John W. Eikelboom, Martin O’Donnell, Salim Yusuf, Rafael Diaz, Greg Flaker, Robert Hart, Stefan Hohnloser, Campbell Joyner, Jack Lawrence, Piern Pias, Janice Pogue, David Synhorst, and Stuart J. Connolly

**354** Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): The first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction
Monica Taljaard, PhD, Michael R. Ward, PhD, Michael J.B. Kutryk, MD, PhD, David W. Courtman, PhD, Nancy J. Camack, RN, MBA, Shaun G. Goodman, MD, MSc, Thomas G. Parker, MD, Alexander J. Dick, MD, Jacques Galipeau, MD, and Duncan J. Stewart, MD, Ottawa, Toronto, and Montreal, Canada

**361** Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events
Tamio Teramoto, MD, PhD, Kazuyuki Shimada, MD, PhD, Shinichiro Uchiyama, MD, PhD, Masahiro Sugawara, MD, Yoshio Goto, MD, PhD, Nobuo Kiyama, MD, PhD, Shindai Okawa, MD, PhD, Tsutomu Ishizaka, MD, PhD, Kenji Yokoyama, MD, PhD, Mitsuru Murata, MD, PhD, and Yasuo Ikeda, MD, PhD, Tokyo, Tochigi, and Ibaraki, Japan
Clinical Investigations

Electrophysiology
370 In-hospital management of patients with atrial flutter
Nancy M. Allen LaPointe, PharmD, Jie-Lena Sun, MS, and Sigal Kaplan, PhD, BPharm, Durham, NC; and Silver Spring, MD

Acute Ischemic Heart Disease
377 Evidence of disparity in the application of quality improvement efforts for the treatment of acute myocardial infarction: The American College of Cardiology’s Guidelines Applied in Practice Initiative in Michigan
Adesuwa B. Olomu, MD, MS, Mary Grzybowski, PhD, MPH, Vijay S. Ramanath, MD, Adam M. Rogers, MD, Bonnie Motyka Vautaw, MS, Benrong Chen, PhD, Canopy Roychoudhury, PhD, Elizabeth A. Jackson, MD, MPH, and Kim A. Eagle, MD for the American College of Cardiology Foundation Guidelines Applied in Practice Steering Committee, East Lansing, Detroit, Farmington Hills, Ann Arbor, and Dearborn, MI; and Lebanon, NH

Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study
Todd M. Brown, MD, MSPH, Jenifer H. Voeks, PhD, Vera Bittner, MD, MSPH, and Monika M. Safford, MD, Birmingham, AL

Differences in mortality in acute coronary syndrome symptom clusters
Barbara Riegel, DNSc, RN, FAAN, Alexandra L. Hanlon, PhD, Sharan McKinley, PhD, RN, Debra K. Moser, DNSc, RN, FAAN, Hendrika Meischke, PhD, Lynn V. Doering, DNSc, RN, FAAN, Patricia Davidson, PhD, RN, Michele M. Peiter, RN, PhD, and Kathleen Dracup, DNSc, RN, FAAN, Philadelphia, PA; Sydney, Australia; Lexington, KY, Seattle, WA; Los Angeles and San Francisco, CA; and Reno, NV

Coronary Artery Disease
399 Cuff and aortic pressure differences during dobutamine infusion: A study of the effects of systolic blood pressure amplification
Harold Smulyan, MD, Ratnakar Mukherjee, MD, Paul R. Sheehe, ScD, and Michel E. Safar, MD, Syracuse, NY; Glen Burnie, MD, and Paris, France

Congestive Heart Failure
406 Relationships between emerging measures of heart failure processes of care and clinical outcomes
Adrian F. Hernandez, MD, MHS, Bradley G. Hammill, MS, Eric D. Peterson, MD, MPH, Clyde W. Yancy, MD, Kevin A. Schulman, MD, Lesley H. Curtis, PhD, and Gregg C. Fonarow, MD, Durham, NC; Dallas, TX; and Los Angeles, CA

414 Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: A cross-sectional study
Margret Leosdottir, MD, Ronnie Willenheimer, MD, PhD, Jonathan Plehn, MD, Rasmus Borgquist, MD, PhD, Petri Guudmundsson, BSc, PhD, Tamara B. Harris, PhD, Lenore J. Launer, PhD, Haliorda Bjorgsdottir, MD, Peter M. Nilsson, MD, PhD, and Vilmundur Guudason, MD, PhD, Malmo and Lund, Sweden; Lung and Blood Institute, NIH; Bethesda, MD; and Kopavogur and Reykjavik, Iceland

Detection of elevated right atrial pressure using a simple bedside ultrasound measure
Marc A. Simon, MS, MD, FACC, Dustin E. Kliner, MD, John P. Girod, DO, Diego Moguilansky, MD, Florencia S. Villanueva, MD, FACC, and John J. Pacella, MS, MD, FACC, Pittsburgh, PA

Propranolol and the risk of hospitalized myopathy: Translating chemical genomics findings into population-level hypotheses
Soko Setoguchi, MD, DrPh, John M. Higgins, MD, Helen Mogun, MS, Vamsi K. Mootha, MD, and Jerry Avorn, MD, Boston, MA
Interventional Cardiology
434 Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: Experience with the point-of-care Platelet Function Assay--100 C/ADP
Catherine M. Moerenhout, MD, Marc J. Claeyys, MD, PhD, Steven Haine, MD, Hielko Miljoen, MD, Johan M. Bosmans, MD, PhD, Francine Vertessen, Katrien Kluppels, Sc, Marc Van der Planken, MD, and Christiaan J. Vrints, MD, PhD, Edegem, Belgium

439 Mechanisms of nonfatal acute myocardial infarction late after stent implantation: The relative impact of disease progression, stent restenosis, and stent thrombosis
Dimitrios Alexopoulos, MD, PhD, FACC, FESC, Ioanna Xanthopoulou, MD, M Cs, Periklis Davlouras, MD, PhD, Anastasia Damelou, MD, Andreas Mazarakis, MD, John Chiladakis, MD, PhD, and George Hahalis, MD, PhD, Patras, Greece

446 Does “late catch-up” exist in drug-eluting stents: Insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents
Kyung Woo Park, MD, PhD, Chi-Hoon Kim, PhD, Hae-Young Lee, MD, PhD, Hyun-Jae Kang, MD, PhD, Bon-Kwon Koo, MD, PhD, Byung-Hee Oh, MD, PhD, Young-Bae Park, MD, PhD, and Hya-Soo Kim, MD, PhD, Seoul, Republic of Korea

454 Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents
Miroslaw Ferenc, MD, Michael Gick, MD, Rolf-Peter Kienzle, MS, Hans-Peter Bestehorn, MD, Klaus-Dieter Werner, MD, Thomas Comberg, MD, Min Zhao, MD, Heinz Joachim Buettner, MD, and Franz-Josef Neumann, MD, Bad Krozingen, Germany

462 Clopidogrel use and clinical events after drug-eluting stent implantation: Findings from the HealthCore Integrated Research Database
John L. Petersen, MD, MHS, John J. Barron, PharmD, Bradley G. Hammill, MS, Mark J. Cziraky, PharmD, Kevin J. Anstrom, PhD, Peter M. Wahl, MS, Eric L. Eisenstein, DBA, Mitchell W. Krucoff, MD, Robert M. Calif, MD, Kevin A. Schulman, MD, and Lesley H. Curtis, PhD, Durham, NC, and Wilmington, DE

Outcomes, Health Policy, and Managed Care
471 Health-related quality of life and long-term mortality in patients treated with percutaneous coronary intervention
Lisanne Schenkeveld, Msc, Susanne S. Pedersen, PhD, Josephine W.I. van Nierop, Msc, Matte J. Lensen, PhD, Peter P.T. de Jaegere, MD, PhD, Patrick W. Serruys, MD, PhD, and Ron T. van Domburg, PhD, The Netherlands

Imaging and Diagnostic Testing
477 Trends in echocardiography utilization in the Veterans Administration Healthcare System
Kingston Okrah, MD, Mary Vaughan-Sarrazin, PhD, and Peter Cram, MD, MBA, Iowa City, IA

484 Temporal trends in compliance with appropriateness criteria for stress single-photon emission computed tomography sestamibi studies in an academic medical center
Raymond J. Gibbons, MD, J. Wells Askew, MD, David Hodge, MSc, and Todd D. Miller, MD, Rochester, MN

Surgery
490 Timing of nonemergent coronary artery bypass grafting and mortality after non-ST elevation acute coronary syndrome
Marc W. Deyell, MD, MSc, William A. Ghali, MD, MPH, David B. Ross, MD, Jianguo Zhang, MSc, and Brenda R. Hemmelgarn, MD, PhD, for the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators, Vancouver, Calgary, and Edmonton, Canada

Continued on page 4A
Valvular and Congenital Heart Disease
497 Factors associated with cardiac conduction disorders and permanent pacemaker implantation after percutaneous aortic valve implantation with the CoreValve prosthesis
Jan Baan, Jr., MD, PhD, Ze Yie Yong, MD, Karel T. Koch, MD, PhD, José P.S. Henriques, MD, PhD, Berto J. Bouma, MD, PhD, Marije M. Vis, MD, Riccardo Cocchieri, MD, Jan J. Piek, MD, PhD, and Bas A.J.M. de Mol, MD, PhD, Amsterdam, The Netherlands

Letters to the Editor

●11 Effect of interval (V-V) optimization in ischemic versus nonischemic patients after cardiac resynchronization therapy
Fu Yi, MD, PhD, Jin Yu, MD, PhD, and Bing Liu, MD, PhD, Xi’an, China

●13 Reply to the Letter to the Editor by Yi et al
Nina Ajmone Marsan, MD and Jeroen J. Bax, MD, PhD, Leiden, The Netherlands

●15 Brain natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure
Viroj Wiwanitkit, Bangkok, Thailand

●17 Author response: B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure
Kevin Rogers, MD MSCI, Aurora, CO

●19 Low vitamin D may explain the link between preeclampsia and cardiovascular disease
William B. Grant, PhD, San Francisco, CA

●21 High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation: A randomized controlled trial evaluating the relationship to endothelial function and inflammation. Am Heart J 2009;158:734-41
Philippe Meyer, MD, Mathieu Gayda, PhD, Éve Normandin, BSc, Thibaut Guiraud, MSc, Martin Juneau, MD, and Anil Nigam, MD, Montreal, Canada